Skip to main content

Table 3 Adverse events

From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

  SRS and Ipilimumab (n = 45) SRS and Nivolumab (n = 35)
Grade 1 or 2 Grade 3 Grade 1 or 2 Grade 3
Number of patients with at least an adverse eventa 31 (68%) 11 (24%) 20 (57%) 6 (17%)
Event
 Diarrhoea 11 (24%) 3 (7%) 5 (14%) 1 (3%)
 Nausea or vomiting 8 (18%) 1 (2%) 4 (12%) 1 (3%)
 Constipation 5 (11%) 0 2 (6%) 0
 Increased AST and/or ALT levels 4 (9%) 2 (4%) 4 (12%) 2 (6%)
 Fatigue 12 (27%) 3 (7%) 6 (18%) 2 (6%)
 Endocrine immune disorders 3 (7%) 0 2 (6%) 0
 Rash/Pruritus 10 (22%) 1 (2%) 6 (18%) 1 (3%)
 Arthralgia 5 (11%) 0 3 (9%) 0
 Muscle weakness right or left sided 3 (7%) 1 (2%) 2 (6%) 1 (3%)
CNS event
 Headache 8 (18%) 2 (4%) 4 (12%) 1 (3%)
 Hemorrhage 3 (7%) 1 (2%) 2 (6%) 1 (3%)
 Seizure 3 (7%) 2 (4%) 2 (6%) 1 (3%)
 Diziness 4 (9%) 0 2 (6%) 0
Brain necrosis 13 (29%) 5 (11%) 7 (20%) 3 (9%)
Discontinuation of treatment 5   3  
  1. aTreatment-related adverse events of any grade occurring in at least 5% of patiens in either cohorts. Some patients had more than one event. No grade 4 events were reported in both cohorts